1
Carl W Gilbert, Myung Ok Cho: Interferon polymer conjugates. Enzon, Roberts & Mercanti, January 27, 1998: US05711944 (128 worldwide citation)

A process is disclosed for preparing long-acting alpha interferon-containing compositions. Alpha interferon is contacted with a relatively small molar excess of a substantially non-antigenic polymer in the presence of a surfactant to preserve bioactivity. Isolation of the desired conjugate species h ...


2
Richard B Greenwald, Carl W Gilbert: Interferon polymer conjugates and process for preparing the same. Enzon, Roberts & Mercanti L, April 14, 1998: US05738846 (126 worldwide citation)

Interferon-polymer conjugate containing compositions having high levels of retained interferon activity and relatively long circulating lives in vivo are disclosed. The compositions contain a mixture of mono-interferon-polymer conjugates and bis-interferon-polymer conjugates, with both species conta ...


3
Terrence W Hallahan, Carl W Gilbert: Factor IX -- polymeric conjugates. Galgano & Burke, October 19, 1999: US05969040 (113 worldwide citation)

Conjugates containing a substance with coagulant activity, such as recombinant Factor IX, non-antigenic polymers, such as poly(ethylene glycol), are disclosed. Also disclosed are methods of forming the novel conjugates of this invention.


4
Terrence W Hallahan, Carl W Gilbert: Factor IX- polymeric conjugates. Galgano & Burke, April 15, 1997: US05621039 (104 worldwide citation)

Conjugates containing a substance with coagulant activity, such as recombinant Factor IX, non-antigenic polymers, such as poly(ethylene glycol), are disclosed. Also disclosed are methods of forming the novel conjugates of this invention.


5
Carl W Gilbert, Myung ok Park Cho: Interferon polymer conjugates. Enzon, Roberts & Mercanti, September 14, 1999: US05951974 (61 worldwide citation)

Compositions containing alpha interferon conjugated to a substantially non-antigenic polymer are disclosed in which at least about 30% of the conjugates include covalent attachment of the alpha interferon to the substantially non-antigenic polymer at a histidine. Also disclosed is a process for prep ...


6
Carl W Gilbert, Myung ok Park Cho: Interferon polymer conjugates. Enzon, Roberts & Mercanti, March 28, 2000: US06042822 (55 worldwide citation)

Compositions containing alpha interferon conjugated to a substantially non-antigenic polymer are disclosed in which at least about 30% of the conjugates include covalent attachment of the alpha interferon to the substantially non-antigenic polymer at a histidine. Also disclosed is a process for prep ...


7
Richard B Greenwald, Carl W Gilbert: .alpha.-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same. Enzon, Roberts & Mercanti, November 9, 1999: US05981709 (46 worldwide citation)

A process for preparing .alpha.-interferon-polymer conjugates having high levels of retained interferon activity and relatively long circulating lives in vivo is disclosed. The process includes forming substantially non-antigenic .alpha.-interferon-polymer conjugates, combining the .alpha.-interfero ...


8
Robert G L Shorr, Carl W Gilbert: Fractionated polyalkylene oxide-conjugated hemoglobin solutions. Enzon, Michael N Mercanti, July 22, 1997: US05650388 (45 worldwide citation)

Polyalkylene oxide-conjugated hemoglobin solutions having a molecular weight greater than about 85,000 daltons and a degree of substitution of which substantially avoids clinically significant nephrotoxicity associated with hemoglobinuria in mammals. A method of simultaneously fractionating and puri ...


9
Robert G L Shorr, Carl W Gilbert, Brian M Martin, Myung Ok Cho, Edward J Ginns: Glycolipid enzyme-polymer conjugates. The United States of America represented by The Department of Health and Human Services, January 6, 1998: US05705153 (10 worldwide citation)

Conjugates containing glucocerebrosidase and non-antigenic polymers such as polyethylene glycol are disclosed. The conjugates circulate for extended times and have prolonged activity in vivo when compared to unmodified enzymes. The conjugates are useful in the treatment of Gaucher's Disease and have ...


10
Robert G L Shorr, Myung Ok Cho, Carl W Gilbert, Edward J Ginns, Brian M Martin: Glycolipid enzyme-polymer conjugates. Enzon, Michael N Mercanti, April 15, 1997: US05620884 (3 worldwide citation)

Conjugates containing glucocerebrosidase and non-antigenic polymers such as polyethylene glycol are disclosed. The conjugates circulate for extended times and have prolonged activity in vivo when compared to unmodified enzymes. The conjugates are useful in the treatment of Gaucher's Disease and have ...